Omeros Corporation (NASDAQ:OMER) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have received a consensus rating of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $18.00.

Several equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research report on Friday, May 16th. HC Wainwright restated a "buy" rating and issued a $9.00 price objective on shares of Omeros in a report on Friday, June 27th. Wall Street Zen cut shares of Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. Finally, D. Boral Capital restated a "buy" rating and issued a $36.00 price objective on shares of Omeros in a report on Monday, June 30th.

Omeros Stock Performance

Shares of NASDAQ OMER traded up $0.28 during midday trading on Friday, hitting $3.93. 1,003,380 shares of the company traded hands, compared to its average volume of 740,104. Omeros has a 12-month low of $2.95 and a 12-month high of $13.60. The stock has a 50-day moving average price of $3.61 and a 200 day moving average price of $6.68. The firm has a market cap of $230.26 million, a P/E ratio of -1.48 and a beta of 2.16.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05). As a group, equities analysts expect that Omeros will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

Hedge funds and other institutional investors have recently bought and sold shares of the business. Truvestments Capital LLC lifted its stake in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Omeros in the fourth quarter worth approximately $46,000. Picton Mahoney Asset Management lifted its stake in shares of Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 4,404 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Omeros by 14,486.3% in the first quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 7,388 shares in the last quarter. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.